Myeloma VII - myelomatosis therapy trial

Medical Research Council (MRC) (UK)0 个研究点目标入组 750 人开始时间: 2000年10月25日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. They have definite myelomatosis requiring chemotherapy and fulfilling at least two of the three following criteria: bone marrow aspirate and/or trephine showing the presence of a neoplastic plasma cell infiltrate and/or microplasmacytomas, a paraprotein present in blood and/or urine
•2. They have definite lytic bone lesions
•3. They are aged under 65 years
•4. They are able to tolerate a daily fluid intake of not less than 3 litres
•5. The physician is satisfied it would be appropriate to receive any of specified treatments

•1. Patients have equivocal myelomatosis (these should be registered but will not receive treatment - if disease progresses then they may be entered into the main trial)
•2. They have previous malignancies except non-melanoma skin tumours or in situ carcinomas
•3. Had previous treatment except minimal local radiotherapy to relieve bone pain
•4. If have a life threatening disease unrelated to myelomastosis.

发起方

Medical Research Council (MRC) (UK)